Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2024-02-14 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving the company's largest shareholder. It provides specific details on collateral providers, debt amounts, and contract terms. This type of disclosure regarding financing arrangements and collateralization of shares falls under the category of capital and financing updates.
2024-02-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (진행성 핵상마비 치료제로서 GV1001의 미국 2b상 임상시험계획(IND) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by GemVax regarding the approval of a Phase 2b clinical trial (IND) by the US FDA. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a formal regulatory announcement of a material corporate event, it is classified as a Regulatory Filing (RNS).
2024-02-13 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding the 'Execution of a Stock Collateral Agreement involving a change in the largest shareholder'. It details specific collateral contracts, loan amounts, and the terms of the pledge. This type of disclosure regarding financing activities, capital structure, and collateralization of shares falls under the 'Capital/Financing Update' category.
2024-02-13 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Pledge of Shares' (collateral) contract involving a change in the major shareholder's status. It provides specific details on collateral providers, debt amounts, and individual contract terms. This falls under 'Capital/Financing Update' as it relates to financing activities and collateralization of shares.
2024-01-19 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and contractual relationships (such as pledges and loans) of major shareholders and their special related parties. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-01-19 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) detailing a 'Correction Report' regarding a 'Collateral Provision Agreement' involving the company's largest shareholder. It provides specific details on share pledges, loan amounts, and collateral terms. This type of disclosure regarding financing arrangements and collateralization of shares by major shareholders is classified under Capital/Financing Update (CAP) as it pertains to the company's capital structure and financing activities.
2024-01-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.